Friday, June 19, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “Bristol Myers Squibb” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 40
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 40 pipeline programs matching "Bristol Myers Squibb" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

40 results for “Bristol Myers Squibb” Back to intelligence hub

Search results

Page 2 of 2
  1. BMS-986466

    Bristol-Myers Squibb

    Advanced Solid Tumors

    phase 2 small molecule terminated

    1 trial
  2. BMS-986504

    Bristol-Myers Squibb

    Solid Tumors

    phase 2 small molecule active

    1 trial
  3. Dasatinib

    Bristol-Myers Squibb

    Chronic Myeloid Leukemia

    phase 2 small molecule completed

    1 trial
  4. Deucravacitinib

    Bristol-Myers Squibb

    Alopecia Areata

    phase 2 small molecule terminated

    1 trial
  5. Nivolumab

    Bristol-Myers Squibb

    Hepatocellular Carcinoma

    phase 2 mab completed

    1 trial
  6. Nivolumab

    Bristol-Myers Squibb

    Prostate Cancer

    phase 2 mab completed

    1 trial
  7. Relatlimab

    Bristol-Myers Squibb

    Neoplasms by Site

    phase 2 mab completed

    1 trial
  8. nivolumab

    Bristol-Myers Squibb

    Neoplasms by Site

    phase 2 mab completed

    1 trial
  9. vinflunine

    Bristol-Myers Squibb

    Transitional Cell Carcinoma

    phase 2 small molecule completed

    1 trial
  10. BMS-641988 (AR#2)

    Bristol-Myers Squibb

    Prostate Cancer

    phase 1 small molecule completed

    1 trial
  11. BMS-906024

    Bristol-Myers Squibb

    Cancer

    phase 1 small molecule completed

    1 trial
  12. BMS-986148

    Bristol-Myers Squibb

    Advanced Cancer

    phase 1 small molecule completed

    1 trial
  13. BMS-986202

    Bristol-Myers Squibb

    Psoriasis

    phase 1 small molecule completed

    1 trial
  14. BMS-986500

    Bristol-Myers Squibb

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial
  15. CC-122

    Bristol-Myers Squibb

    Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial
  16. Nivolumab

    Bristol-Myers Squibb

    Melanoma

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.